Introduction {#s1}
============

All tuberculosis (TB) patients ought to be tested for human immunodeficiency virus (HIV), but compliance with this recommendation has not yet been achieved in Canada or globally. In 2010 nationally, and in 2011 internationally, an HIV test result was reported in only 40% of TB patients [@pone.0098993-The1], [@pone.0098993-World1]. A lack of compliance was understandable before the availability of highly active anti-retroviral therapy (HAART) and in the context of discrimination, when informed consent and extensive pre- and post-test counseling were advised. More recently, however, these factors have been mitigated and both counseling and testing are considered part of routine medical care. Not knowing the HIV status of prevalent active TB cases has the potential to compromise TB management, outcomes and elimination [@pone.0098993-World1], [@pone.0098993-UNAIDS1]. As such, poor compliance with the recommendation that all TB patients be HIV tested is now indefensible.

In response to two national advisories and the close biological and epidemiological links between HIV and TB, an 'opt-out' approach to HIV testing of TB patients was introduced in Alberta, a Province of Western Canada, in 2002--2003 [@pone.0098993-Canadian1], [@pone.0098993-The2]. HIV testing is defined as 'universal' if \>80% of incident TB cases were tested annually [@pone.0098993-Horsburgh1]--[@pone.0098993-Long1]. The 'opt-out' approach implemented in Alberta was patterned after an established program of 'opt-out' HIV testing of prenatal women [@pone.0098993-Jayaraman1], and is similar to the 'provider-initiated' HIV testing program recommended by the United Nations Programme on HIV/AIDS and World Health Organization (UNAIDS/WHO) in 2004 and 2007 for countries with high co-infection rates [@pone.0098993-UNAIDSWHO1], [@pone.0098993-WHOUNAIDS1]. This approach is characterized by two stages: 1) patients are briefly informed about the connection between HIV and TB and the clinical and prevention benefits of being tested and 2) the routine testing of TB patients for HIV unless their provider is actively informed of the patient\'s decision not to be tested.

We describe ten years of experience with universal 'opt-out' HIV testing of TB patients in Alberta. In addition to identifying risk factors for HIV seropositivity, the demographic, clinical and laboratory characteristics of TB patients who were newly diagnosed versus previously diagnosed with HIV are compared. Finally, we describe the extent to which clustering and/or cluster size, markers of recent transmission, predict HIV co-infection in the host using molecular epidemiologic techniques.

Methods {#s2}
=======

Persons meeting the Canadian case definition for TB [@pone.0098993-The1], and notified in the Province of Alberta (population 3,645,257 in 2011, Statistics Canada) over the 10-year period 2003 to 2012, were identified. In addition to HIV test results the following demographic and clinical information were abstracted from the Provincial TB Registry for each case: age, sex, population group, disease type (new active versus relapse/re-infection), first-line drug resistance, disease site, (respiratory, non-respiratory or both, according to the Canadian TB Standards) and mortality [@pone.0098993-The1]. Population groups in this study include Canadian-born Aboriginal (First Nations \[North American Indian\], Métis or Inuit according to the Constitution Act of 1982), Canadian-born 'other', foreign-born from sub-Saharan Africa (as per the Canadian International Development Agency at: <http://www.acdi-cida.gc.ca/subsaharanafrica>) and foreign-born 'other'. The proportion of all TB patients and TB patients aged 15 to 64 years who were HIV tested before and after the introduction of 'opt-out' testing, was related to the timing of two national advisories and the availability of HAART. All HIV testing of TB patients was performed in the Provincial Laboratory for Public Health (ProvLab) using conventional methods. Risk factors for HIV co-infection are described; in a multivariable model an *a priori* set of variables was retained.

For HIV co-infected patients data from individual health records supplements those data abstracted from the TB Registry (see below). HIV co-infected TB patients are divided into those who were known to be HIV-positive in the past and those who were discovered to be HIV positive during the 3 months immediately preceding their date of diagnosis of TB or during the period of active treatment of TB. The window for a "new positive" HIV test permits TB being unmasked or diagnosed during the early investigation and management of HIV [@pone.0098993-Girardi1]--[@pone.0098993-Manabe1]. TB patients with *known* positive HIV tests were compared to TB patients with *new* positive HIV tests on the basis of age, sex, population group, disease type, CD4 count, viral load (≤400 copies/ml -- a viral load that is generally associated with controlled HIV infection on antiretroviral therapy \[ARV\'s\] and accounts for changing testing methodology; 401--100,000 copies/ml -- moderately advanced HIV infection, and \>100,000 copies/ml -- the recognized cutoff for advanced HIV infection), hepatitis C serology, HIV exposure category and mortality. Results indicate whether TB patients were on ARVs at the time of diagnosis of TB.

Isolates of *M. tuberculosis* from all culture-positive cases of TB diagnosed in the Province of Alberta between 2003 and 2012 are routinely DNA fingerprinted using standardized restriction fragment-length polymorphism (RLFP), supplemented in those isolates with five or fewer copies of the insertion sequence *6110*, by spoligotyping [@pone.0098993-VanEmbden1], [@pone.0098993-Dale1]. Images were digitalized using the imager video camera system (Appligene, Illkirch, France). Digitalized gel images were analyzed using Gelcompar II computer software (Applied Maths, Kortrijk, Belgium). The analysis was performed on coded specimens in a blinded fashion. All isolates matched as identical by computer were manually confirmed by visually comparing the original autoradiographs. 'Clusters' are defined as two or more case isolates with identical DNA fingerprints over either (i) the entire 10-year "opt-out" testing period or (ii) within two years of one another. For the latter we chronologically ordered the TB cases in each genotypic cluster by the date of diagnosis of each culture-positive case. We assumed that the first case of respiratory TB in a cluster resulted from reactivation of latent TB infection and was the source case patient. Subsequent respiratory and/or non-respiratory cases in the same genotypic cluster likely resulted from recent transmission and rapid progression to disease and were defined as secondary cases if they occurred within 24 months of the sourse case or each other [@pone.0098993-DeRiemer1], [@pone.0098993-LangloisKlassen1]. For each definition of a cluster, mean cluster size was compared by age, sex, population group, HIV status and population-group-by-HIV-status-interaction.

Statistical Analysis {#s2a}
--------------------

Fisher\'s exact test, where necessary, was used to compare proportions. To compare the demographic and clinical characteristics of HIV-negative and HIV-positive TB patients between 2003 and 2012, odds ratios (OR) with 95% confidence intervals were reported. Purposeful selection method was used to select the variables included in the multivariable logistic regression model [@pone.0098993-Hosmer1]. Age, sex, population group, disease type and site, drug resistance, and mortality were tested for potential confounding effect. Wald\'s test was used to test the significance of each variable in the model. Generalized estimating equation (GEE) with identity link and independent correlation was used to account for clustering with the same strain, to estimate the mean cluster size after adjusting for age, sex, population group and HIV status. A p-value of 0.05 was used as statistically significant. All analyses were conducted using Stata (StataCorp. 2011. Stata Statistical Software: Release 12. College Station, TX: StataCorp LP). This study was approved by the Health Research Ethics Board of the University of Alberta. A waiver of written consent was provided as anonymous, routinely collected surveillance data were used.

Results {#s3}
=======

Between 1991 and 2002 the proportion of TB patients who were HIV tested averaged 26.1% (see [Figure 1](#pone-0098993-g001){ref-type="fig"}). In 1996--1997 the introduction of HAART and in 2002--2003 the introduction of "opt-out" HIV testing, resulted in sharp increases in the proportion of TB patients who were HIV tested. In 2003, and annually thereafter, "universal" HIV testing of TB patients was achieved (average 90.6%; range 74.8% to 100% overall and average 94.9%; range 84.8% to 100% in the age group 15--64 years). Of the 1317 TB patients who were HIV tested between 2003 and 2012, 74 (5.6%) were HIV-positive (see [Table 1](#pone-0098993-t001){ref-type="table"}). Independent of sex or population group, TB patients in the age group 15--64 years were more likely to be HIV tested than TB patients in the age groups 0--14 years or \>64 years (94.9% vs. 74.7%, p\<0.001; and 94.9% vs. 81.3%, p\<0.001, respectively). CBO were less likely to be HIV tested than other population groups but the difference was not statistically significant after adjustment for age. For patients who did not undergo HIV testing (n = 136), the test was not offered in 39 (28.7%), declined in 13 (9.6%), and in the remainder the reason for not testing was unknown. For patients who were not offered the test, 14 (35.9%) were diagnosed with TB at death and 16 (41.0%) were either younger than 15 or older than 64 years of age. For patients who declined HIV testing there was no consistent pattern in their demographic characteristics.

![The absolute number of TB patients that were HIV tested (left axis) and the proportion of TB patients who were HIV tested (right axis) by year in Alberta, 1991--2012.](pone.0098993.g001){#pone-0098993-g001}

10.1371/journal.pone.0098993.t001

###### HIV status of TB patients in Alberta by demographic group, 2003--2012.

![](pone.0098993.t001){#pone-0098993-t001-1}

  Demographic group    TB Cases   HIV tested[\*](#nt103){ref-type="table-fn"}   HIV Positive[†](#nt104){ref-type="table-fn"}  
  ------------------- ---------- --------------------------------------------- ---------------------------------------------- -----------
  Total                                              1453                                       1317 (90.6)                    74 (5.6)
  Age (years)                                                                                                                 
                        0--14                         75                                         56 (74.7)                     01 (1.8)
                        15--34                        458                                        443 (96.7)                    21 (4.7)
                        35--64                        577                                        539 (93.4)                    51 (9.5)
                         \>64                         343                                        279 (81.3)                    01 (0.4)
  Sex                                                                                                                         
                         Male                         748                                        685 (91.6)                    45 (6.6)
                        Female                        705                                        632 (89.6)                    29 (4.6)
  Population group                                                                                                            
                         CBO                          154                                        130 (84.4)                    01 (0.8)
                         CBA                          182                                        167 (91.8)                    16 (9.6)
                         FBO                          854                                        771 (90.3)                    15 (2.0)
                        FBSSA                         263                                        249 (94.7)                    42 (16.9)

Abbreviations: CBO =  Canadian-born \'Other\'; CBA =  Canadian-born Aboriginal; FBO = Foreign-born \'Other\';

FBSSA = Foreign-born sub-Saharan African.

\*Percent of all TB cases.

Percent of HIV-tested TB cases.

Among HIV tested TB patients in the age group 15--64 years, 72/910 or 7.9% were HIV-positive (see [Table 2](#pone-0098993-t002){ref-type="table"}). This seroprevalence was not significantly different from the one we reported in 1991-2002 (28/342 or 8.2%, p = 0.87) when much more selective testing was performed, suggesting, in the absence of major secular trends, that HIV co-infection may have been missed in the earlier era [@pone.0098993-Sturtevant1]. In the age group 15--64, those aged 35--64 years were more likely than those aged 15--34 years (9.5% vs. 4.7%, p\<0.001) to be HIV co-infected in multivariate analysis (see [Table 2](#pone-0098993-t002){ref-type="table"}). Similarly, Canadian-born Aboriginal or foreign-born sub-Saharan Africans were more likely than Canadian-born or foreign-born 'other' (12.5% vs. 2.2% and 18.3 vs. 2.2%, p\<0.001 and p\<0.001, respectively) to be HIV co-infected. Finally, patients with respiratory and non-respiratory TB combined were more likely than patients with respiratory TB alone (20.0% vs. 7.0%, p = 0.01), and patients reported as a TB death were more likely than patients not reported as a TB death (30.4% vs. 6.8%, p = 0.043) to be HIV co-infected. In contrast, HIV positive and negative TB patients did not differ by sex, disease type and presence of drug resistance.

10.1371/journal.pone.0098993.t002

###### Risk Factors for HIV Seropositivity in TB patients aged 15--64 years, Alberta, 2003--2012.

![](pone.0098993.t002){#pone-0098993-t002-2}

  Characteristic                                         HIV-negative       HIV-positive (%)   Univariate OR (95% CI; p-value)   Multivariate OR (95% CI; p-value)  
  -------------------------------------------------- --------------------- ------------------ --------------------------------- ----------------------------------- -----------------------------
  Age (years)                                                                                                                                                       
                                                            15--34                422                     21 (4.7)                             1.00                             1.00
                                                            35--64                488                     51 (9.5)                    2.1 (1.24, 3.55; 0.006)         3.3 (1.83, 5.96; \<0.001)
  Sex[\*](#nt107){ref-type="table-fn"}                                                                                                                              
                                                            Female                453                     29 (6.0)                             1.00                             1.00
                                                             Male                 457                     43 (8.6)                     1.47 (0.9, 2.4; 0.12)           1.59 (0.94, 2.71; 0.09)
  Population Group[†](#nt108){ref-type="table-fn"}                                                                                                                  
                                                              CBO                  76                      1 (1.3)                             1.00                             1.00
                                                              FBO                 535                     13 (2.4)                                                  
                                                              CBA                 112                     16 (12.5)                 6.23 (2.96, 13.13; \<0.001)      5.42 (2.49, 11.82; \<0.001)
                                                             FBSSA                187                     42 (18.3)                 9.8 (5.24, 18.34; \<0.001)       13.9 (7.14, 27.0; \<0.001)
  Disease Type                                                                                                                                                      
                                                          New Active              853                     70 (7.6)                             1.00                              \-
                                                      Relapse/Retreatment          57                      2 (3.4)                    0.43 (0.1, 1.79; 0.19)                     \-
  Drug Resistance[‡](#nt109){ref-type="table-fn"}                                                                                                                   
                                                              No                  647                     53 (7.6)                             1.00                              \-
                                                              Yes                 119                     10 (7.8)                    1.02 (0.51, 2.07; 0.94)                    \-
                                                            Unknown               144                      9 (5.9)                              \-                               \-
  Disease Site                                                                                                                                                      
                                                          Respiratory             545                     41 (7.0)                             1.00                             1.00
                                                        Non-respiratory           329                     22 (6.3)                    0.89 (0.52, 1.52; 0.6)           0.93 (0.52, 1.65; 0.8)
                                                             Both                  36                     9 (20.0)                    3.32 (1.5, 7.37; 0.003)         3.32 (1.29, 8.53; 0.013)
  Mortality[§](#nt110){ref-type="table-fn"}                                                                                                                         
                                                              No                  892                     65 (6.8)                             1.00                             1.00
                                                              Yes                  18                     7 (30.4)                  6.02 (2.39, 15.15; \<0.001)        2.80 (0.96, 8.15;0.059)

Abbreviations: CBO  =  Canadian-born \'Other\'; CBA  =  Canadian-born Aboriginal; FBO  =  Foreign-born \'Other\';

FBSSA  =  Foreign-born sub-Saharan African.

\*By convention, sex was retained in the multivariable model. Its exclusion in the multivariable model did not affect the significance of other variables

CBO and FBO were combined in the analysis as HIV prevalence rates were similarly low in both groups and the number of CBO cases was small

Resistance to one or more first-line drug; cases whose drug resistance pattern was unknown were culture-negative.

Death before or during the period of active treatment of TB.

Of the 74 TB patients determined to be HIV co-infected in 2003-2012, 38 (51.4%) were known to have been HIV-positive prior to the diagnosis of TB and 36 (48.6%) were discovered to be HIV-positive at the time of diagnosis of TB (see [Table 3](#pone-0098993-t003){ref-type="table"}). Those with known HIV positivity and those with new HIV positivity did not differ with respect to age, sex, population group, exposure category or mortality in univariate analysis. With respect to other characteristics, however, there were notable differences between groups. Compared to known HIV-positive cases, new HIV-positive cases were more likely to have respiratory TB in combination with non-respiratory TB, a low CD4 count (\<200×10^6^/L) and a high viral load (\>100,000 HIV RNA copies/ml); odds ratios and 95% confidence intervals 2.71(1.04, 6.99), 7.65(1.92, 30.5), and 12.7(1.32, 121.5), respectively. In patients with an ARV utilization history, 14 of 34 (41.2%) with known HIV positivity and none of 31 (0.0%) with new HIV positivity, were on ARV\'s at the time of diagnosis of TB (see [Figure S1](#pone.0098993.s001){ref-type="supplementary-material"}). TB patients with new HIV positivity were less likely than TB patients with known HIV positivity to be HCV positive, 8.6% vs 28.6% (0.23; 0.06, 0.94). In data that is not shown, HCV positivity was strongly correlated with IDU, 11 of 13 (84.6%) with IDU versus 0 of 36 (0.0%) without IDU, were HCV positive (p\<0.0001). And IDU was strongly correlated with population group; of the 53 HIV positive TB patients whose exposure category was known, 11/14 (78.6%) Aboriginal peoples versus 2/39 (5.1%) persons of other population groups, reported IDU (p\<0.001).

10.1371/journal.pone.0098993.t003

###### Demographic and clinical characteristics of HIV co-infected TB patients according to the date of diagnosis of HIV relative to the date of diagnosis of TB[\*](#nt112){ref-type="table-fn"}.

![](pone.0098993.t003){#pone-0098993-t003-3}

  Characteristics                                              Total        Known HIV(+ve)[\*](#nt112){ref-type="table-fn"}   New HIV(+ve)[\*](#nt112){ref-type="table-fn"}   Odds ratio (95% CI; p-value)  
  ------------------------------------------------------ ----------------- ------------------------------------------------- ----------------------------------------------- ------------------------------ --------------------------
  No. assessed (%)                                              74                                38                                               36                                      \-               
  Age (years)                                                                                                                                                                                               
                                                               \<35                               22                                            14 (36.8)                              08 (22.2)             0.49 (0.17, 1.36, 0.17)
                                                                ≥35                               52                                            24 (63.2)                              28 (77.8)                       1.00
  Sex                                                                                                                                                                                                       
                                                              Female                              29                                            18 (47.4)                              11 (30.6)                       1.00
                                                               Male                               45                                            20 (52.6)                              25 (69.4)             2.04 (0.79, 5.31, 0.14)
  Population group                                                                                                                                                                                          
                                                                CBO                               01                                            01 (2.6)                                0 (0.0)                 Included with FBO
                                                                CBA                               16                                            10 (26.3)                              06 (16.7)             0.36 (0.09, 1.51, 0.16)
                                                                FBO                               15                                            05 (13.2)                              10 (27.8)                       1.00
                                                               FBSSA                              42                                            22 (57.9)                              20 (55.6)             0.54 (0.17, 1.77, 0.31)
  Disease site                                                                                                                                                                                              
                                                            Respiratory                           42                                            26 (68.4)                              16 (44.4)                       1.00
                                                          Non-Respiratory                         23                                            09 (23.7)                              14 (38.9)             2.71 (1.04, 6.99, 0.04)
                                                               Both                               09                                            03 (7.9)                               06 (16.7)              Included with Non-Resp
  CD4 count [†](#nt113){ref-type="table-fn"}                                                                                                                                                                
                                                               \<200                              43                                            17 (44.7)                              26 (72.2)             7.65 (1.92, 30.5, 0.004)
                                                               ≥200                               18                                            15 (39.5)                               03 (8.3)                       1.00
                                                              Unknown                             13                                            06 (15.8)                              07 (19.4)                        \-
  HIV RNA (copies/ml) [‡](#nt114){ref-type="table-fn"}                                                                                                                                                      
                                                               ≤400                                7                                            06 (15.8)                               01 (2.8)                       1.00
                                                           401--100,000                           21                                            14 (36.8)                               7 (19.4)              3.0 (0.30, 30.0, 0.35)
                                                             \>100,000                            28                                            09 (23.7)                              19 (52.8)             12.7 (1.32, 121.5, 0.03)
                                                              Unknown                             18                                            09 (23.7)                              09 (25.0)                        \-
  Hepatitis C                                                                                                                                                                                               
                                                                Pos                               13                                            10 (28.6)                               03 (8.6)             0.23 (0.06, 0.94, 0.04)
                                                                Neg                               57                                            25 (71.4)                              32 (91.4)                       1.00
                                                              Unknown                             04                                            03 (7.9)                                01 (2.8)                        \-
  Exposure category [§](#nt115){ref-type="table-fn"}                                                                                                                                                        
                                                                HSS                               36                                            17 (44.7)                              19 (52.8)                       1.00
                                                                IDU                               13                                            10 (26.3)                               03 (8.3)             0.27 (0.06, 1.14, 0.07)
                                                               Other                              04                                            03 (7.9)                                01 (2.8)             0.30 (0.03, 3.14, 0.31)
                                                              Unknown                             21                                            08 (21.1)                              13 (36.1)            
  Mortality                                                                                                                                                                                                 
                                                             No death                             66                                            33 (86.8)                              33 (91.7)                       1.00
                                                               Died                               08                                            05 (13.2)                               03 (8.3)              0.6 (0.13, 2.72, 0.51)

abbreviations: CBO Canadian-born \'other\'; CBA Canadian-born Aboriginal; FBO foreign-born \'other\'; FBSSA foreign-born sub-Saharan African; IDU injection drug use; HSS heterosexual sex.

\*The date of diagnosis of TB is defined as the start date of treatment; see text for definition of "known" vs. "new" HIV-positive

Refers to the number of CD4 receptor-bearing lymphocytes ×10^6^/L; only measurements made up to three months before or one month after the start date of treatment of TB were accepted. If multiple measurements were made in this time period the measurement closest to the date of diagnosis of TB was used.

Quantitative HIV viral loads were assessed in the Provincial Laboratory for Public Health; only measurements made up to three months before or one month after the start date of treatment of TB were accepted. If multiple measurements were made in this time period the measurement closest to the date of diagnosis of TB was used.

2 HSS also listed 'transfusion'; 10 IDU also listed \'heterosexual\'; 'other' exposure categories included 2 men who have sex with men, and 2 vertical exposure.

Of the 1453 patients diagnosed with TB between 2003 and 2012, 228 (15.7%) were culture-negative, 18 (1.2%) were culture-positive for MTB complex species other than *M. tuberculosis* and 1207 (83.1%) were culture-positive for *M. tuberculosis* (see [Figure S2](#pone.0098993.s002){ref-type="supplementary-material"}). HIV co-infection varied by culture status; 5/228 (2.2%) if culture-negative, 3/18 (16.7%) if culture-positive for MTB complex species other than *M. tuberculosis* and 65/1207 (5.4%) if culture-positive for *M. tuberculosis*. Of the *M*. *tuberculosis* isolates, 1202 (99.7%) were DNA fingerprinted (65 \[5.4%\] from HIV-positive patients, 1042 \[86.7%\] from HIV-negative patients and 95 \[7.9%\] from HIV-unknown patients). Of the 1107 HIV tested cases with DNA fingerprinted isolates 759 cases exhibited unique fingerprint patterns (non-clustered cases) and 348 (31.4%) clustered cases were dispersed among 104 clusters, when the analysis of clustering was unconstrained by time; i.e. any genotypic match over 10 years was accepted. Eighteen clusters (96 cases) involved one or more HIV-positive case (median cluster size 3.5 [@pone.0098993-World1]--[@pone.0098993-Dale1] cases); 86 clusters (252 cases) involved HIV-negative cases only (median cluster size 2.0 [@pone.0098993-World1]--[@pone.0098993-LangloisKlassen1] cases), p\<0.03 (see [Figure 2](#pone-0098993-g002){ref-type="fig"}). Only one cluster involved both CBA and FBSSA cases. Using the same unconstrained cluster analysis mean cluster size did not differ by age, sex or HIV status (see [Table 4](#pone-0098993-t004){ref-type="table"}). Mean cluster size was, however, much larger in Aboriginal peoples compared to other population groups, and within Aboriginal peoples, larger in those who were HIV-positive compared to those who were HIV-negative. When the cluster analysis was constrained by time (i.e. clustered cases had to have occurred within 24 months of one another \[see [Methods](#s2){ref-type="sec"}\], thus better reflecting recent transmission, cluster size was again much larger in Aboriginal peoples, but within Aboriginal peoples an HIV interactive effect was no longer seen.

![TB patients in Alberta who were culture-positive for *Mycobacterium tuberculosis*, whose isolates were DNA fingerprinted, and who were HIV tested (n = 1107) by clustering.](pone.0098993.g002){#pone-0098993-g002}

10.1371/journal.pone.0098993.t004

###### Mean cluster size by demographic group, HIV status and population group-HIV status interaction in Alberta, 2003--2012.

![](pone.0098993.t004){#pone-0098993-t004-4}

                                                                         Clustering with no time frame   Clustering with 2-yr time frame                
  -------------------------------------------- ------------------------ ------------------------------- --------------------------------- ------------- ------
  Age                                                                                                                 0.23                               0.45
                                                      \<15 years                  3.50 (0.56)                                               2.7 (0.5)   
                                                     15--34 years                 2.58 (0.16)                                              2.08 (0.15)  
                                                     35--64 years                 2.63 (0.15)                                              2.1 (0.13)   
                                                      \>64 years                  2.33 (0.21)                                              1.89 (0.18)  
  Sex                                                                                                                 0.15                               0.13
                                                         Male                     2.69 (0.13)                                              2.18 (0.12)  
                                                        Female                    2.43 (0.14)                                              1.93 (0.12)  
  Population group                                                                 \<0.0001                                                 \<0.0001    
                                                         CBA                      6.88 (0.25)                                              5.38 (0.23)  
                                                      CBO & FBO                   1.82 (0.12)                                              1.49 (0.11)  
                                                        FBSSA                     1.98 (0.23)                                              1.61 (0.2)   
  HIV Status                                                                                                          0.54                               0.51
                                                     HIV-negative                 2.57 (0.10)                                              2.07 (0.09)  
                                                     HIV-positive                 2.38 (0.58)                                              1.82 (0.52)  
  Population group by HIV-status interaction                                         0.017                                                    0.11      
                                                   CBA HIV-negative               6.76 (0.26)                                              5.3 (0.24)   
                                                   CBA HIV-positive               8.81 (0.78)                                              6.58 (0.7)   
                                                CBO & FBO HIV-negative            1.85 (0.12)                                              1.52 (0.1)   
                                                CBO & FBO HIV-positive            1.34 (0.83)                                              1.02 (0.75)  
                                                  FBSSA HIV-negative              2.02 (0.24)                                              1.64 (0.21)  
                                                  FBSSA HIV-positive              1.34 (0.53)                                              1.15 (0.47)  

Abbreviations: CBA Canadian-born Aboriginal; CBO Canadian-born 'other'; FBO foreign-born 'other'; FBSSA foreign-born sub-Saharan African.

\*Significance of difference between categories obtain from Wald chi-squared test in multivariate analysis.

Discussion {#s4}
==========

In the time period and jurisdiction of this study, the routine 'opt-out' HIV testing of TB patients was very well received, with only 9.4% of incident TB cases not being tested. Similar to experience in the United States, TB patients at the extremes of age (\<15 and \>64 years) were less likely to be tested [@pone.0098993-Centre1]. In those who were HIV tested the prevalence of HIV was 5.6%, almost identical to the rate estimate made for Canada by the WHO in 2007 (5.7%) [@pone.0098993-World2]. In the age group 15--64 years, which included 97.3% of the co-infected patients, HIV was more common in those aged 35--64 years, Canadian-born Aboriginal or foreign-born sub-Saharan African (HIV prevalence\'s 12.5% and 18.3%, respectively), those with combined respiratory and non-respiratory TB, and those who died. Compared to patients with known HIV positivity, patients with new HIV positivity at the time of diagnosis of TB, had more advanced HIV disease (lower CD4 counts; higher viral loads). Median cluster size was greater when clusters contained one or more HIV-positive case than when clusters contained HIV-negative cases only. Mean cluster size was greater in HIV-positive versus HIV-negative Aboriginal peoples.

In the WHO\'s package of collaborative TB/HIV activities aimed at reducing the burden of TB/HIV, TB patients are recommended to be HIV tested [@pone.0098993-PolicyoncollaborativeTBHIV1], [@pone.0098993-World3]. Quite appropriately, UN/AIDS/WHO pronouncements on provider-initiated ('opt-out') HIV counseling and testing of TB patients have focused on countries with high co-infection rates where the potential return on HIV testing of TB patients is greatest in terms of preventing morbidity, mortality and sustained transmission [@pone.0098993-UNAIDSWHO1], [@pone.0098993-WHOUNAIDS1], [@pone.0098993-Chaisson1]. Despite some difficulties in implementation such as the structural and personal factors described by Pope et al. in South Africa [@pone.0098993-Pope1], [@pone.0098993-Pope2], a remarkable 69% of TB patients in the African Region had a documented HIV test result in 2011 [@pone.0098993-World1]. In high income countries such as Canada co-infection rates are lower, limiting the potential impact of screening, but the resources necessary to maximize the clinical and prevention benefits of screening are more readily available. Since 1989 in the US and 1992 in Canada, national advisories have recommended universal HIV testing of TB patients [@pone.0098993-Canadian1], [@pone.0098993-The2], [@pone.0098993-Centre2]. In Alberta, the availability of ART in 1996--1997 and the introduction of 'opt-out' HIV testing in 2002--03, the latter facilitated by centralized clinical and laboratory TB services [@pone.0098993-Jensen1], resulted in universal HIV testing of TB patients. Though the prevalence of HIV co-infection was low at the extremes of age and in those who were Canadian-born non-Aboriginal or foreign-born from countries other than those in sub-Saharan Africa, rates in all of these groups were still \>0.1%, the rate above which testing is considered cost-effective [@pone.0098993-Sanders1], [@pone.0098993-Moyer1]. Nationally, it is unknown whether the low proportion of TB patients with a reported HIV test result is due to a failure to record the test result, to offer the test, or to the test being declined, once offered [@pone.0098993-The1]. Differences in the organization of TB programs in Canada\'s provinces and territories and perhaps some under-appreciation of TB as a clinical opportunity for HIV testing [@pone.0098993-LongRLangloisKlassen1], may otherwise explain the low proportion of TB patients that are HIV tested in Canada.

Universal HIV testing of TB patients allowed us to further refine our understanding of the risk factors for co-infection of TB patients in Alberta and by extrapolation, other major immigrant-receiving provinces of Canada. As in earlier analyses, age and population group emerged as significant risk factors [@pone.0098993-Sturtevant1], [@pone.0098993-Long1]. Higher HIV co-infection rates in middle-aged versus young adult TB patients is understood to reflect not only age at HIV acquisition but more immunologically advanced disease and therefore higher risk of TB associated with years of living with HIV (see below). The latest recommendations of the CDC and the US Preventive Services Task Force, which are in turn based upon evidence that earlier initiation of ART (when CD4 counts are between 200 and 500×10^6^/L), is associated with reduced risk for AIDS-related events or deaths [@pone.0098993-Moyer1], [@pone.0098993-Branson1], suggests that broader, more inclusive testing is the direction Canada should be taking. In this regard, the US has for some time now recommended HIV testing of TB contacts [@pone.0098993-Centers1]; more recently this has been shown to be feasible, using either conventional or point-of-care testing methods [@pone.0098993-Gardner1], [@pone.0098993-Person1].

The high HIV prevalence in Aboriginal TB patients is especially troubling; Aboriginal peoples in Canada are known to be at higher risk for latent TB infection and the penetration of HIV into this subpopulation has the potential to aggravate what is already an unsatisfactory state of TB control [@pone.0098993-The1]. Though HIV testing is part of the immigration medical examination in Canada, it is unlikely to result in the exclusion of the applicant [@pone.0098993-Zencovich1]. The high HIV co-infection rate in immigrants to Alberta from sub-Saharan Africa with TB is not altogether unexpected [@pone.0098993-Chaisson1]. The prevalence does, however, add weight to the argument that all immigrants and refugees with HIV infection ought to be referred for medical surveillance for both HIV and TB as a condition of entry to Canada. That TB patients with combined respiratory and non-respiratory TB or TB patients that died, were more likely to be HIV co-infected was not surprising [@pone.0098993-The1], [@pone.0098993-Sturtevant1], [@pone.0098993-Centre1].

Though the number of HIV co-infected TB patients was relatively small, representing a potential study limitation, a new diagnosis of HIV was just as common as a known diagnosis of HIV. Within the limitations of the data (small numbers; missing data) those with a new diagnosis of HIV and therefore without ART, were as expected, more likely to be immunosuppressed and to have both respiratory and non-respiratory disease combined. This notwithstanding, many of those known to have been HIV positive in the past were immunosuppressed and not on ARVs at the time of diagnosis of TB. The reasons for this and the possibility that TB may have been prevented in these patients and those with a new diagnosis of HIV, had they been HIV tested earlier as a TB contact, will be explored in a separate communication. Screening persons with HIV for TB at regular intervals, allowing for earlier diagnosis and treatment of TB, might lower mortality [@pone.0098993-Reid1]. Diagnosing HIV in contacts followed by treatment with ART and TB preventive therapy might prevent TB [@pone.0098993-Akolo1]. As expected, HCV was closely associated with IDU, placing this subpopulation of the HIV co-infected at greater risk of anti-TB drug induced liver injury [@pone.0098993-Staples1]. That IDU was commonly reported in HIV-positive Aboriginal TB patients suggests that efforts to prevent IDU-related HIV infection might also prevent TB in this population group.

In earlier studies HIV was shown to increase the risk of belonging to a cluster of TB cases [@pone.0098993-Alland1], [@pone.0098993-Jasmer1], but not to affect the size of clusters [@pone.0098993-Giordano1]. More recently, in a study from San Francisco, median cluster size was shown to be larger when clusters involved one or more HIV-positive case than when clusters involved HIV-negative cases only; within the homeless population HIV was judged to be a key factor sustaining TB transmission [@pone.0098993-DeRiemer1], [@pone.0098993-Mohtashemi1]. In Alberta, where being of Aboriginal ancestry is well known to be associated with clustering [@pone.0098993-Kunimoto1], cluster size was much larger in Aboriginal peoples, but within Aboriginal peoples there was no HIV interactive effect. In earlier studies in Alberta no association between Beijing strains and either transmission or HIV was found[@pone.0098993-LangloisKlassen1], [@pone.0098993-LangloisKlassen2]. In contrast to HIV endemic countries, where most TB in HIV-positive persons is thought to result from recent transmission [@pone.0098993-Houben1], the large proportion of 'un-clustered' HIV-positive patients (almost all foreign-born) in our study suggests that reactivation TB is the predominate pathogenic mechanism for HIV-related TB in high income immigrant-receiving countries. Dual control measures would appear to be indicated based on population groups, emphasizing prevention of transmission in Aboriginal peoples and treatment of latent infection in the foreign-born.
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